Atezolizumab plus bevacizumab (A plus B) as first-line systemic therapy for advanced hepatocellular carcinoma (HCC): A multi-institution analysis of patient outcomes based on Child Pugh (CP) and ALBI liver function

被引：0
|
作者：
Storandt, Michael H.
Zemla, Tyler J.
Patell, Kanchi
Naleid, Nikolas
Gile, Jennifer
Tran, Nguyen H.
Chakrabarti, Sakti
Jin, Zhaohui
Mahipal, Amit
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Case Western Reserve Univ, Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA
[3] Univ Hosp Cleveland Med Ctr, Dept Internal Med, Cleveland, OH USA
[4] Mayo Clin, Div Med Oncol, Rochester, MN USA
[5] Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA
[6] Case Western Reserve Univ, Univ Hosp Seidman Canc Ctr, Dept Oncol, Cleveland, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4099
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
    C-H Hsu
    T-S Yang
    C Hsu
    H C Toh
    R J Epstein
    L-T Hsiao
    P-J Chen
    Z-Z Lin
    T-Y Chao
    A-L Cheng
    British Journal of Cancer, 2010, 102 : 981 - 986
  • [22] Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore
    Chee, Cheng Ean
    Khara, Jasmeet Singh
    Cheong, John
    Fong, Jek
    Sivanesan, Sivabalan
    Choy, Jian Yi
    Hu, Meibo
    Viswambaram, Amrita
    Toh, Han Chong
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (05) : 631 - 641
  • [23] Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis
    Li, Yan
    Liang, Xueyan
    Li, Huijuan
    Chen, Xiaoyu
    CANCER, 2022, 128 (22) : 3995 - 4003
  • [24] Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
    Hsu, C-H
    Yang, T-S
    Hsu, C.
    Toh, H. C.
    Epstein, R. J.
    Hsiao, L-T
    Chen, P-J
    Lin, Z-Z
    Chao, T-Y
    Cheng, A-L
    BRITISH JOURNAL OF CANCER, 2010, 102 (06) : 981 - 986
  • [25] Is atezolizumab plus bevacizumab as first-line therapy for unresectable hepatocellular carcinoma superior to lenvatinib? a systematic review and meta-analysis
    Zhu, Gang
    Zeng, Longfei
    Yang, Liu
    Zhang, Xin
    Tang, Jinquan
    Pan, Yong
    Li, Bo
    Chen, Mengchen
    Wu, Tao
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (10) : 1425 - 1434
  • [26] HIGHER RISK OF PROTEINURIA IN ATEZOLIZUMAB PLUS BEVACIZUMAB THAN LENVATINIB AS A FIRST-LINE SYSTEMIC TREATMENT IN UNRESECTABLE HEPATOCELLULAR CARCINOMA
    Yang, Jiwon
    HEPATOLOGY, 2024, 80
  • [27] Atezolizumab plus Bevacizumab after first-line multikinase inhibitors for advanced hepatocellular carcinoma: The concept of "drug class change"
    Saitta, Carlo
    Cabibbo, Giuseppe
    DIGESTIVE AND LIVER DISEASE, 2023, 55 (07) : 831 - 832
  • [28] Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients
    Chen, Yen-Hao
    Chen, Yen-Yang
    Wang, Jing-Houng
    Hung, Chao-Hung
    ANTICANCER RESEARCH, 2023, 43 (03) : 1377 - 1384
  • [29] Survival outcomes from Atezolizumab plus Bevacizumab versus Lenvatinib versus Sorafenib in Child Pugh B unresectable hepatocellular carcinoma patients
    Rimini, Margherita
    Persano, Mara
    Tada, Toshifumi
    Suda, Goki
    Shigeo, Shimose
    Kudo, Masatoshi
    Cheon, Jaekyung
    Finkelmeier, Fabian
    Lim, Ho Yeong
    Presa, Jose
    Lonardi, Sara
    Piscaglia, Fabio
    Chon, Hong Jae
    Masi, Gianluca
    Scartozzi, Mario
    Cascinu, Stefano
    Casadei-Gardini, Andrea
    JOURNAL OF HEPATOLOGY, 2023, 78 : S592 - S592
  • [30] Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety
    Shao, Yu-Yun
    Feng, Yin-Hsun
    Yen, Chia-Jui
    Yang, Tsai-Sheng
    Shen, Ying-Chun
    Chao, Yee
    Chen, Jen-Shi
    Su, Ching-Yen
    Chen, Wei-Jen
    Hsiang, Hwa-Lin
    Hsu, Chih-Hung
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2022, 121 (12) : 2430 - 2437
12345